Could 2017 be a pivotal year for RNAi? According to Ali Mortazavi, the chief executive of Silence Therapeutics Plc, this is a strong possibility if upcoming data from the trial of a short interfering RNA (siRNA) molecule being developed by Alnylam Pharmaceuticals Inc are positive.
